Objective: Genetic testing for cancer risk will shortly enter medical practice. Our intent was to increase the understanding of the public’s attitudes towards and potential demand for genetic testing. Methods: We conducted a random-digit-dial survey of 1,450 adults in Washington State to assess the public’s attitudes toward genetic testing for cancer risk and to investigate correlates of intention to be tested for breast cancer risk (women) and prostate cancer risk (men). No specific genes were mentioned, as the intent of the survey was to understand the general interest in screening for genetic risks. The survey addressed familiarity with genetic testing, intention to be tested for breast or prostate cancer risk (when tests become available), benefits and risks associated with genetic tests, and who should have access to test results. Results: Most respondents expressed the intention to be tested for breast or prostate cancer risk (women 76%, men 83%). Most women (83%) and men (74%) would give the results to their primary care physician, but fewer believed that the test results should be available to their employer (women 5%, men 9%), their health insurer (women 32%, men 31%), or family members (women 42%, men 43%). Over 60% worried that discrimination could arise from genetic testing. Correlates of intention to be tested for breast cancer (women) included a family history of breast cancer, lower education, poor health, a history of mammography screening, and more physician visits in the past year. Among men, correlates of intention to test for prostate cancer included higher income, previous cancer diagnosis, a history of PSA screening, and more physician visits in the past year. Respondents who strongly believed in the benefits of genetic testing, who perceived themselves at greater risk for having a gene that increases risk, or who were less worried about discrimination expressed greater intent to be tested. Conclusions: Our survey suggests that the demand for genetic tests for cancer risk may be high, although confidentiality of test results is a major concern. Health care providers, genetic counselors, and research institutions should prepare strategies and policies for genetic testing and counseling as these tests enter general medical practice.

Keywords:
Genetic testing, Cancer, Attitudes, Population survey, Random digit dialing, Health policy
1.
Goate AM, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991;349:704–706.
2.
Dunlop MG: Colorectal cancer genetics. Semin Cancer Biol 1992;3:131–140.
3.
Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, et al: Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 1992;258:668–671.
4.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.
5.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–792.
6.
Holtzman NA, Murphy PD, Watson MS, Barr PA: Predictive genetic testing: From basic research to clinical practice. Science 1997;278:602–605.
7.
Vineis P, McMichael A: Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer. Cancer Causes Control 1996;7:479–486.
8.
Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R: Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098–1102.
9.
Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC, Hunter DJ: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862–4864.
10.
Eng C, Vijg J: Genetic testing: The problems and the promise. Nat Biotechnol 1997;15:422–426.
11.
Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al: BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes. JAMA 1996;275:1885–1892.
12.
Croyle RT, Smith KR, Botkin JR, Baty B, Nash J: Psychological responses to BRCA1 mutation testing: Preliminary findings. Health Psychol 1997;16:63–72.
13.
Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, et al: A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 1997;79:2219–2228.
14.
Hopwood P: Psychological issues in cancer genetics: Current research and future priorities. Patient Educ Couns 1997;32:19–31.
15.
Geller G, Botkin JR, Green MJ, Press N, Biesecker BB, Wilfond B, Grana G, Daly MB, Schneider K, Kahn MJ: Genetic testing for susceptibility to adult-onset cancer: The process and content of informed consent. JAMA 1997;277:1467–1474.
16.
Task Force on Genetic Testing: Promoting Save and Effective Genetic Testing in the United States, Final Report. Bethesda, National Institutes of Health, 1997.
17.
Genesys Sampling Systems: An Introduction to the GENESYS Sampling System. Fort Washington, Genesys Sampling Systems, 1995.
18.
Troldahl VC, Carter RE: Random selection of respondents within households in phone surveys. J Market Res 1964;1:71–76.
19.
Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J: Random digit dialing in selecting a population-based control group. Am J Epidemiol 1984;120:825–833.
20.
Andersen R: A Behavioral Model of Families’ Use of Health Services. Chicago, University of Chicago Press, 1968.
21.
Agresti A: Analysis of Ordinal Categorical Data. New York, Wiley, 1984.
22.
Lerman C, Seay J, Balshem A, Audrain J: Interest in genetic testing among first-degree relatives of breast-cancer patients. Am J Med Genet 1995;57:385–392.
23.
Croyle RT, Lerman C: Interest in genetic testing for colon cancer susceptibility: Cognitive and emotional correlates. Prev Med 1993;22:284–292.
24.
Hietala M, Hakonen A, Aro AR, Niemelä P, Peltonen L, Aula P: Attitudes toward genetic testing among the general population and relatives of patients with a severe genetic disease: A survey from Finland. Am J Hum Genet 1995;56:1493–1500.
25.
Smith KR, Croyle RT: Attitudes toward genetic testing for colon cancer risk. Am J Public Health 1995;85:1435–1438.
26.
Andrykowski MA, Munn RK, Studts JL: Interest in learning of personal genetic risk for cancer: A general population survey. Prev Med 1996;25:527–536.
27.
Andrykowski MA, Lightner R, Studts JL, Munn RK: Hereditary cancer risk notification and testing: How interested is the general population? J Clin Oncol 1997;15:2139–2148.
28.
Tambor ES, Rimer BK, Strigo TS: Genetic testing for breast cancer susceptibility: Awareness and interest among women in the general population. Am J Med Genet 1997;68:43–49.
29.
Aro AR, Hakonen A, Hietala M, Lonnqvist J, Niemelä P, Peltonen L, Aula P: Acceptance of genetic testing in a general population: Age, education and gender differences. Patient Educ Couns 1997;32:41–49.
30.
Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-Caminero A, Hughes C, Reed MM: Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 1997;89:148–157.
31.
Klijn JG, Devilee P, Van-Geel AN, Tilanus-Linthorst MM, Dudok-de-Wit C, Meijers-Heijboer EJ: Initial Dutch results with presymptomatic DNA tests in familial breast/ovarian carcinoma. Ned Tijdschr Geneeskd 1995;139:439–445.
32.
Watson M, Murday V, Lloyd S, Ponder B, Averill D, Eeles R: Genetic testing in breast/ovarian cancer (BRCA1) families (letter). Lancet 1995;346:583.
33.
Bratt O, Kristoffersson U, Lundgren R, Olsson H: Sons of men with prostate cancer: Their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing. Urology 1997;50:360–365.
34.
Richards CS, Ward PA, Roa BB, Friedman LC, Boyd AA, Kuenzli G, Dunn JK, Plon SE: Screening for 185delAG in the Ashkenazim. Am J Hum Genet 1997;60:1085–1098.
35.
Bernhardt BA, Geller G, Strauss M, Helzlsouer KJ, Stefanek M, Wilcox PM, et al: Toward a model informed consent process for BRCA1 testing: A qualitative assessment of women’s attitudes. J Genet Couns 1997;6:207–222.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.